Clinical data
ATC code None
CAS Number 119431-25-3 N
PubChem (CID) 60703
ChemSpider 54708 YesY
ECHA InfoCard 100.162.249
Chemical and physical data
Formula C20H23ClFNO
Molar mass 347.854 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Eliprodil (codenamed SL-82.0715) is a NMDA antagonist drug candidate that failed a Phase III clinical trial for the treatment of acute ischemic stroke in 1996, sponsored by Synthélabo Recherche.[1][2][3]

NMDA receptors are a key component in mediating glutamate-induced excitotoxicity, and it is believed that NMDA antagonists would be neuroprotective after a stroke or other traumatic brain injury.[4] After a traumatic brain injury, neurons become deprived of glucose and oxygen. These neurons quickly lose ATP and become depolarized, which releases glutamate. The intracellular buildup of glutamate triggers the overstimulation of AMPA and NMDA receptors. This, in turn, causes an influx of Na+ and Ca2+. Therefore, when NMDA receptors are activated, there is an increase in intracellular Ca2+ concentration. High Ca2+ causes fatal metabolic consequences, including neuronal cell death.[3]


  1. The Pharma Letter. 2 December 1996 Synthelabo's Eliprodil Fails In Stroke Trials
  2. DeKeyser J, Sulter G, & Luiten PG (1999) Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends in neurosciences 22(12):535-540 PMID 10542428
  3. 1 2 Lee JM, Zipfel GJ, & Choi DW (1999) The changing landscape of ischaemic brain injury mechanisms. Nature 399(6738 Suppl):A7-14 PMID 10392575
  4. Ikonomidou C & Turski L (2002) Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? The Lancet. Neurology 1(6):383-386 PMID 12849400
This article is issued from Wikipedia - version of the 12/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.